CervoMed: Regulation Fd Disclosure, The Information Set Forth In The First And Third Paragraphs Of, And Under The Headings “analyses Reinforce Observed Treatment Effect Of Neflamapimod In ‘pure’ Dlb And Support Planned Phase 3 Dose” And “neflamapimod Demonstrated Durable Slowing Of Basal Forebrain Atrophy,” And In The First, Second, Third, Fourth, And Sixth Paragraphs Under The Heading “new Pkpd Analysis And Phase 2 Study Results For Neflamapimod 80 Mg Bid In Dlb Strengthen Understanding Of Dosing” In, The Company’s Press Release Issued On July 14, 2026, Is Incorporated By Reference Into This Item 8.01 Of This Currentreportonform8k, Financial Statements And Exhibits

Mostra articolo completo

Questa funzionalità è disponibile solo per gli utenti registrati

• Nome completo dell'emittente
  CervoMed Inc
• Paese di registrazione
  USA
• Settore industriale
  Pharmaceutical Preparation and Biotechnology
• М/S&P/F
  *** / *** / ***